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EVALUATION OF GBV-C / HGV VIREMIA IN HIV-INFECTED WOMEN
Synara Araújo SILVA(2), Célia Lima RODRIGUES(1,2), Aléia Faustino CAMPOS(2) & José Eduardo LEVI(1,2) 
SUMMARY
The present study aimed at standardizing a real-time quantitative polymerase chain reaction assay to evaluate the presence of 
GBV-C/HGV RNA. A “TaqMan” assay using primers and probe derived from the 5′ NCR region was developed and validated. 
Two hundred and fifty-three plasma samples from HIV-infected women were tested for GBV-C viremia and antibody against 
the envelope protein 2. GBV-C RNA was detected in 22.5% of the patients whereas the antibody was identified in 25.3% of the 
cohort. Detection of viral RNA and of antibodies was mutually exclusive. Viral loads showed a mean of 1,777 arbitrary units / 
mL, being 1.1 and 13,625 arbitrary units / mL respectively the lowest and highest values measured. We conclude that the real-time 
quantitative polymerase chain reaction method developed is appropriate for the investigation of GBV-C RNA since it was shown 
to be highly specific and sensitive, as well as requiring few steps, preventing contamination and providing additional information 
as to the relative viremia of carriers, a parameter that must be included in studies evaluating the co-factors influencing the clinical 
outcome of HIV/AIDS.
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BACKGROUND
The GB virus C (GBV-C) or Hepatitis-G Virus (HGV), a member of 
the Flaviridae family, has a single-stranded positive-sense RNA genome 
with 9400 nucleotides. Two isolates of this virus were described in 
concomitance by two different groups working at diagnostic companies 
trying to identify a putative virus responsible for the remaining 
cases of non A-H hepatitis12,17. Soon after the characterization of 
both agents, it became evident that they were closely related, but the 
nomenclature was not unified. However, after extensive research, it 
became evident that GBV-C is not a hepatotropic virus, since it in fact 
replicates in lymphocytes5. Moreover, no human disease was related to 
GBV-C, including hepatitis. Therefore, the name Hepatitis G virus is 
inappropriate, so GBV-C will be used in this report.
GBV-C is prevalent worldwide in healthy populations such as blood 
donors but also in specific groups of patients like HIV-infected subjects 
(reviewed in15). It is transmitted mainly by sexual contact but also 
parenterally, which explains the high prevalence found in intravenous 
drug users and patients submitted to multiple transfusions16.
There are refined techniques for detecting GBV-C as a Transcriptase 
Polymerase Chain Reaction (RT-PCR) for the viral genome. An 
immunoassay (EIA) detecting antibodies to putative GBV-C envelope 
protein E2 (anti-E2) has been developed in the past and its use nowadays 
is restricted to research19. The combined use of RT-PCR and EIA has 
allowed for more comprehensive epidemiological studies of the true 
status and natural course of GBV-C infection8.
Viremia may persist for years, however 60-75% of immunocompetent 
persons present spontaneous clearance of GBV-C, and this event usually 
coincides with the development of antibodies against the GBV-C surface 
envelope glycoprotein E2. Thus, antibody presence is inversely correlated 
to RNA viral detection and anti-E2 antibodies serve as a recovery marker 
in acute and chronic GBV-C infection.
The beneficial effect of the co-infection by the GBV-C/HGV in HIV-
infected subjects has been under intense scrutiny and debate over the last 
few years, after the first demonstration of its protective role by several 
research groups around the world6,9,21. Several studies corroborated these 
findings23 while a few others failed to substantiate them22. More recently, 
a meta-analysis has tried to summarize most of the experimental data 
regarding this issue and concluded that GBV-C does exert a protective 
effect in the evolution to AIDS in HIV-infected individuals, independent of 
several potential confounders26. In experimental studies, GBV-C infection 
of peripheral-blood mononuclear cells resulted in decreased replication of 
both clinical and laboratory HIV strains that use either CCR5 or CXCR4 as 
their co-receptor. GBV-C induces HIV inhibitory chemokines and reduces 
the expression of HIV co-receptor CCR5 in vitro, that could block or 
reduce the decline of CD4 counts, hence justifying the better prognosis24,25.
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We have been accompanying a cohort of HIV-infected women since 
1997, and decided to investigate whether GBV-C status could have 
influenced survival rates in this cohort. Bearing this in mind, we came to 
the conclusion that the expected high prevalence of GBV-C RNA carriers 
among this population could blur the alleged biological effect caused by 
this virus. Quantification of GBV-C RNA would allow one to observe a 
gradient of effect and also compare HIV quantitative laboratorial markers 
like viral load and CD4 counts to GBV-C viremia.
MATERIAL AND METHODS
1. Samples: We evaluated two hundred and fifty-three plasma samples 
collected between 1997 and 1999 from HIV-infected women enrolled in 
studies on Human Papillomavirus and cervical disease10. Samples have 
been stored at -70 oC since then, with no thawing. Informed consent was 
obtained from all participants. This study was approved by the IRB of 
both recruiting hospitals.
2. RNA extraction and cDNA synthesis: RNA was extracted from 
140 µL of plasma using the QIAamp Viral RNA mini kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s protocol. RNA was eluted in 
60 µL of buffer AVE and stored at -70 oC or directly submitted to cDNA 
synthesis. The reverse transcription employed Moloney Murine Leukemia 
Virus Reverse Transcriptase 2.5 U/µL (M-MLV RT, Invitrogen, São 
Paulo, Brazil) and Random Hexamers 2.5 µM (Invitrogen, São Paulo, 
Brazil). The mixture was incubated for 10 minutes at room temperature, 
then 30 minutes at 37 oC degrees and finally boiled for five minutes. Five 
µL of cDNA contains 2.5 µL of the extracted RNA which ultimately 
corresponds to 5.8 µL of sera.
3. Measurement of ANTI-E2 antibodies in serum: ANTI-E2 
antibodies to GBV-C envelope protein E2 were detected by using 
the µPlate antiHGenv test, Roche Diagnostics (Penzburg, Germany) 
according to the manufacturer’s instructions.
4. Nested-PCR GBV-C: In the first round, 5 µL of cDNA, as above, 
was directly used in a 25 µL final volume PCR reaction containing 200 ηM 
of the primers G58 (sense; 5’-CAGGGTTGGTAGGTCGTAAATCC-3’) 
and G75 (antisense 5’-CCTATTGGTCAAGAGAGA CAT - 3’), 0.2 µM 
of dNTPs, 2.5 mM of MgCl2, 1 Unit of Taq Platinum (Invitrogen, São 
Paulo, Brazil), 5% glycerol and cresol red 0.1 µg/µL. The first round 
generated a fragment of 367 bp. 5 µLs of the product of the first round 
was used as a template for the second round which employed primers 
G134 (sense 5’-GGTCAYCYTGGTAGCCACTATAGG-3’) and G131 
antisense (5’-AAGAGAGACATTGWAGGGCGACGT- 3’) under the 
same conditions as in the first round. A fragment of 208 bp is expected 
for samples containing GBV-C RNA1. Cycling parameters were 95 ºC 
for five minutes, followed by 25 cycles at 94 ºC for 45 seconds, 55 ºC 
for 45 seconds, 72 ºC for 90 seconds and a final elongation step of 72 
ºC for five minutes. All reactions were run in an Eppendorf Gradient 
Mastercycle thermocycler (Eppendorf, Germany).
5. Quantitative Real Time PCR for GBV-C
5.1. TaqMan Assay: GBV-C 5´Non coding region was chosen as a 
target for primer design since it was shown by several groups to be the 
most conserved region of GBV-C among different isolates13. This region 
was submitted to the Primer Express software (Applied Biosystems, 
Foster City, USA) and several combinations of primers and probes were 
retrieved. Each possibility was analyzed visually in order to choose the set 
containing the least nucleotide variability, checked against an alignment 
of GBV-C 5´NCR sequences. We also valued the primer/probe set where 
those differences, if unavoidable, would be placed at the first 5’ positions 
of the oligonucleotides, where they are less prone to interfere with the 
hybridization of the template. Finally, the following assay was produced:
Sense primer RTG1 (5’GTGGTGGATGGGTGATGACA3’); Antisense 
primer RTG2 (5’GACCCACCTATAGTGGCTACCA3’) and probe 
(5’FAM-CCGGGATTTACGACCTACC-NFQ3’) where NFQ stands for 
“non-fluorescent quencher”. ABI provides this assay as a 20X concentrated 
mix. We added 9 µL of cDNA to 10 µL of TaqMan Universal PCR Master 
Mix 2X and 1 µL of the 20X TaqMan assay that contains primers at 360 µM 
and the probe at 100 µM. Cycling conditions were at 95ºC for 10 minutes, 
followed by 40 cycles at 95 ºC for 15 seconds, and 60 ºC for one minute.
5.2 Reference material: A 350 mL plasma bag previously identified 
as containing high titers of GBV-C RNA was kindly provided by the 
Hospital Sírio Libanês Blood Bank (São Paulo, Brazil). Serial dilutions 
of this bag, with normal plasma non-reactive for GBV-C RNA and 
other markers currently screened in the blood bank, that neat down to 
1: 1 000 000, were tested in replicates on the real-time assay as above. 
It was observed that the dilution of 10 000x was detected at a 100% hit 
rate so the value of one arbitrary unit was attributed to this dilution and 
consequently the viral load of the original plasma bag became 10 000 
arbitrary units / mL of GBV-C RNA. To generate the standard curve 
we employed 3 RNA extractions of the neat plasma, plus 1:10, 1:100, 
1:1 000, 1:10 000 and 1:100 000 dilutions.
RESULTS
1. Seroprevalence: Among the two hundred and fifty-three samples 
analyzed for the presence of anti-E2 antibody, sixty-four were considered 
reactive, one hundred and forty-six non-reactive and the remaining 
forty-three indeterminate. Upon repetition, all but five indeterminate 
were shown to be non-reactive, totaling sixty-nine positive samples. 
According to the manufacturer recommendation, a confirmatory assay 
was performed, consisting of the same steps as the regular assay, but 
omitting the incubation with E2 antigen. Cases remaining reactive in this 
test are considered false-positives, which was observed in five samples. 
Thus, the antibody prevalence encountered was 64/253 = 25.3%).
2. Nested- PCR: Fifty-seven samples presented the 208 bp amplicon 
from the GBV-C RNA, in duplicate, corresponding to a prevalence of 
57/253 = 22.5%. The concomitant finding of GBV-C RNA and anti-E2 
antibody was not observed in any sample. Table 1 summarizes the findings 
on both methods.
3. TaqMan assay
3.1. Sensitivity: Since there is no GBV-C RNA standard available, 
we used a plasma bag as a reference material. We obtained Cts < 40 
in all replicates on the 1:10,000 dilution and above. An aliquot of the 
reference material diluted 10,000x was included in all runs. The run was 
accepted if the standard curve met the parameters of R2 ≥ 0.99 and a 
Slope ≤ -3.3, and the running control presented a Ct of 38 ± 1. Figure 1 
shows the Standard Curve graphic of a routine run.
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3.2 Specificity: Twenty samples known to contain hepatitis C virus 
RNA were submitted to this assay and all were shown to be non-reactive. 
Other samples known to contain RNA from two other flaviviruses, namely 
dengue and yellow fever, were also submitted to the assay resulting in 
no amplification. Moreover, experimental samples contained HIV-RNA 
in a wide range of viral loads, and no cross-reactivity was noticed, as 
several samples harboring high HIV-RNA loads were non-reactive for 
this GBV-C quantitative assay.
3.3. Linearity and reproducibility: The assay showed some degree 
of inhibition in the presence of high amounts of GBV-C RNA, as the 
amplification from the neat plasma bag resulted in Cts higher than 
those observed in a 1:5 dilution. This obliged us to re-test all samples 
displaying Cts below thirty at a 1:5 dilution in addition to the pure 
plasma. All replicates in the same experiment, but also in different 
runs beginning from extraction, resulted in variability below one Ct. 
The same fifty-seven samples reactive for nested-PCR were positive 
for this assay, resulting in a 100% concordance for both molecular 
methods. The highest viral load observed was 13,625 while the lowest 
was 1.1 arbitrary units/mL.
All samples with a measurable viral load (N = 57) are shown in Table 
2, in addition to the corresponding CD4 cell counts and HIV-1 viral load.
Table 1 
Results for the serology and molecular analysis Summary of the combined 
analysis for the four possible serology/PCR status (α = anti-E2, RNA± = PCR 
positive for both PCR techniques, Real-Time Taman assay and conventional 
nested-PCR)
Serology/PCR Results N %
α + / RNA + 0 0.00%
α + / RNA – 64 25.30%
α – / RNA + 57 22.53%
α – / RNA – 132 52.17%
TOTAL 253 100.00%
Fig. 1 - Standard curve of GBV-C RNA Real-Time PCR assay. Each point corresponds 
to triplicates of the reference plasma containing 1, 10, 100 and 1 000 arbitrary Units/mL.
Table 2
GBV-C viral load, CD4 counts and HIV viral load in the 57 patients with 
detectable GBV-C RNA.
ID# GBV-C Viral load 
au/mL
CD4/µL  HIV-1 Viral load 
cps/mL
254
15
20
205
114
247
109
242
237
12
263
62
45
6
228
219
116
103
220
182
99
155
239
245
227
231
168
105
236
185
232
246
235
25
47
104
209
110
171
119
172
88
212
30
128
148
230
130
186
197
151
64
213
66
157
81
70
1.1
2.79
2.81
4.63
5.88
9.06
9.32
16.37
16.46
23.34
23.43
25.16
38.32
41.02
43.13
45.09
52.08
56.13
77.22
91.97
110.77
139.73
178.17
195.28
233.51
275.99
285.92
438.7
458.93
493.88
576.59
604.04
619.8
637.06
812.89
820.29
853.43
910.52
1221.35
1221.67
1339.76
1467.71
1589.9
1638.68
1710.4
1895.83
1916.43
2336.16
2769.24
3899.52
3974.57
4318.85
4430.64
4477.56
4511.69
12015.04
13625.37
353
341
361
146
230
219
108
293
443
175
74
258
57
168
272
38
293
506
155
319
512
304
508
437
308
449
135
676
296
189
305
507
89
317
365
228
300
623
500
487
445
284
375
410
379
108
208
314
254
332
355
235
271
333
655
355
237
920
22578
3455
29006
46323
100
47420
5971
2720
49347
942
111173
502
2267
28546
100
481653
378307
4436
10744
130637
4153
13091
13151
42000
7607
100
2404
2467
499
100
100
100
16878
13042
33951
100
19435
100
4604
5840
810
858
40763
477
100
100
100
100
4738
1411
100
100
56116
1165
81986
4451
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DISCUSSION
The unequivocal beneficial effect that GBV-C infection exerts over 
the course of HIV/AIDS renewed the interest for laboratorial methods to 
diagnose and measure this agent on HIV -infected hosts. The prevalence 
of GBV-C RNA in the HIV-infected population is much higher than that 
observed in healthy subjects, with greater geographical variations. In 
Brazil we and others described a prevalence close to 10% among blood 
donors2,11 while in Europe and North America a prevalence of 1-4% 
was verified15. In contrast, 14-43% of HIV-infected subjects harbor 
the viral RNA. Availability of a serological test (anti-E2) allowed for a 
more comprehensive view of GBV-C’s natural history, permitting the 
identification of individuals with past exposure to this agent. Moreover, 
the observation that this antibody would have a protective role and/or is 
a marker of viral clearance makes it mandatory to evaluate both markers 
when estimating GBV-C prevalence.
In this study, a similar prevalence of antibody (22.5%) and RNA 
(25.3%) was observed, resembling what has been described in other 
groups of individuals with impaired immunity, which may be ascribed to a 
lower clearance rate, when compared with immunocompetent populations 
where a rate of viremia to antibody of 1:6 is generally observed23.
Another source of variability in the assessment of GBV-C prevalence, 
besides the population investigated, is the diagnostic method itself. 
A multicentre study on molecular detection of GBV-C displayed a 
wide range of sensitivity and specificity achieved among participating 
laboratories7. Primer selection is a key point in the development of 
successful PCR strategies. Authors comparing genomic regions and 
different primers among the same target gene in the GBV-C genome 
concluded that the 5’UTR is the most stable and conserved region 
and in addition provided a valuable suggestion of “best primers”1,3,18. 
The TaqMan assay here described achieved the same sensitivity as a 
nested-PCR proposed by ANDONOV et al.1, in a more convenient and 
automated format. Moreover, it allows for the quantitation of GBV-C 
RNA which has not been attempted in other publications. Although we 
cannot provide an absolute viral load value, aliquots of this standard are 
available upon request, and  may allow our assay to be calibrated against 
other reference materials. The range of GBV-C viremia was similar to 
what is observed for other RNA viruses causing chronic infection such as 
HIV and HCV. Of course this could reflect the fact that we have analyzed 
a single sample from each individual, which could hide the fluctuation 
that may occur over time. One of the few studies that measured GBV-C 
viremia20 found values ranging between 67,000 and 143,000,000 copies/
mL, a range of 4 log10 in the same magnitude as we describe, although 
the exact correlation between their GBV-C copy and our arbitrary unit 
cannot be assessed, if one considers one copy = one arbitrary unit our 
values would be distributed in between 10,000 and 136,250,000 copies/
mL. CASTELAIN et al. also used a TaqMan real-time PCR method to 
quantify GBV-C genomes in polytrasnsfused children. In contrast to our 
results, they found on average, much higher titers, what may be a sign 
of the source of infection4.
A convenient, sensitive and reproducible Real-Time PCR method was 
developed for GBV-C RNA detection and quantitation. The application 
of this assay has shown its importance as a parameter for the evaluation 
of factors influencing the outcome of HIV/AIDS disease14.
RESUMO
Avaliação da viremia por GBV-C/HGV em mulheres infectadas 
pelo HIV
Este estudo teve como objetivo o desenvolvimento de método de 
PCR em Tempo Real para a determinação da viremia do vírus GBV-C. 
Ensaio baseado em primers e sonda “TaqMan” derivados da região 5’ 
não-codificante deste vírus foi padronizado, validado e aplicado em uma 
série de 253 amostras de plasma de pacientes HIV+. Além do PCR em 
tempo real, as amostras foram submetidas a um ensaio imunoenzimático 
anti-E2 e a um nested-PCR. Das 253 amostras testadas, 64 foram 
positivas para o anticorpo anti-E2 (25,3%), enquanto 57 amostras foram 
concordantemente RNA positivas pelo nested-PCR e PCR em tempo real 
(22,5%), perfazendo um índice total de exposição de 48% (25.3 + 22.5). 
A carga viral teve média de 1.777 UA/mL (13.625 - 1.1UA/mL). 
Foi obtida metodologia simples, rápida e de boa sensibilidade e 
especificidade, permitindo a quantificação do RNA do vírus GBV-C 
com reprodutibilidade. A metodologia permite a análise simultânea de 
grande número de amostras, sendo apropriada para estudos clínicos. A 
prevalência de exposição a este agente na população feminina HIV+ 
estudada é alta, provavelmente decorrente da via sexual comum de 
transmissão dos agentes. 
ACKNOWLEDGMENTS
We would like to thank Dr Dietmar Zdunek (Roche, Penzberg, 
Germany) for his generous gift of anti-HGenv kits.
This study was funded by the Fundação de Amparo a Pesquisa do 
Estado de São Paulo (FAPESP), grant number 05/01072-9.
DECLARATION OF COMPETING INTERESTS
The authors declare that they have no competing interests.
REFERENCES
 1. Andonov A, Sauder C, Jacobsen H. Chaudhary R. Comparison of six sets of PCR primers 
from two different genomic regions for amplification of GB virus C/hepatitis G virus 
RNA. J Clin Microbiol. 1998;36:286-9. 
 2. Bassit L, Kleter B, Ribeiro-dos-Santos G, Maertens G, Sabino E, Chamone D, et al. 
Hepatitis G virus: prevalence and sequence analysis in blood donors of São Paulo, 
Brazil. Vox Sang. 1998;74:83-7. 
 3. Bortolin MT, Zanussi S, Tedeschi R, Pratesi C, D’Andrea M, Bidoli E, et al. Evaluation 
of three molecular biology-based assays for the detection of GB virus C/hepatitis G 
virus in clinical specimens. Intervirology. 2004;47:314-20. 
 4. Castelain S, Francois C, Bonte D, Baron A, Horle B, Morel, V, et al. Epidemiological 
and quantitative study of GBV-C infection in French polytransfused children. J Med 
Virol. 2004;73:596-600.
 5. Fan X, Xu Y, Solomon H, Ramrakhiani S, Neuschwander-Tetri BA, Di Bisceglie AM. 
Is hepatitis G/GB virus-C virus hepatotropic? Detection of hepatitis G/GB virus-C 
viral RNA in liver and serum. J Med Virol. 1999;58:160-4.
 6. Heringlake S, Ockenga J, Tillmann HL, Trautwein C, Meissner D, Stoll M, et al. GB virus 
C/hepatitis G infection: a favorable prognostic factor in human immunodeficiency 
virus-infected patients? J Infect Dis. 1998;177:1723-6.
SILVA, S.A.; RODRIGUES, C.L.; CAMPOS, A.F. & LEVI, J.E. - Evaluation of GBV-C/HGV viremia in HIV-infected women. Rev. Inst. Med. Trop. Sao Paulo, 54(1): 31-5, 2012. 
35
 7. Lefrère JJ, Lerable J, Mariotti M, Bogard M, Thibault V, Frangeul L, et al. Lessons from 
a multicentre study of the detectability of viral genomes based on a two-round quality 
control of GB virus C (GBV-C)/hepatitis G virus (HGV) polymerase chain reaction 
assay. J Virol Methods. 2000;85:117-24.
 8. Lefrère JJ, Loiseau P, Maury J, Lasserre J, Mariotti M, Ravera N, et al. Natural history 
of GBV-C/hepatitis G virus infection through the follow-up of GBV-C/hepatitis G 
virus-infected blood donors and recipients studied by RNA polymerase chain reaction 
and anti-E2 serology. Blood. 1997;90:3776-80.
 9. Lefrère JJ, Roudot-Thoraval F, Morand-Joubert L, Petit JC, Lerable J, Thauvin M, 
et al. Carriage of GB virus C/hepatitis G virus RNA is associated with a slower 
immunologic, virologic, and clinical progression of human immunodeficiency virus 
disease in coinfected persons. J Infect Dis. 1999;179:783-9.
 10. Levi JE, Fernandes S, Tateno AF, Motta E, Lima LP, Eluf-Neto J, et al. Presence of 
multiple human papillomavirus types in cervical samples from HIV-infected women. 
Gynecol Oncol. 2004;92:225-31.
 11. Levi JE, Contri DG, Lima LP, Takaoka DT, Garrini RH, Santos W, et al. High prevalence 
of GB virus C/hepatitis G virus RNA among Brazilian blood donors. Rev Inst Med 
Trop Sao Paulo. 2003;45:75-8.
 12. Linnen J, Wages J Jr, Zhang-Keck ZY, Fry KE, Krawczynski KZ, Alter H, et al. Molecular 
cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. 
Science. 1996;271:505-8.
 13. Linnen JM, Fung K, Fry KE, Mizokami M, Ohba K, Wages JM Jr, et al. Sequence 
variation and phylogenetic analysis of the 5’ terminus of hepatitis G virus. J Viral 
Hepat. 1997;4:293-302.
 14. Maidana-Giret MT, Silva TM, Sauer MM, Tomiyama H, Levi JE, Bassichetto KC, et al. 
GB virus type C infection modulates T-cell activation independently of HIV-1 viral 
load. AIDS. 2009;23:2277-87. 
 15. Mohr EL, Stapleton JT. GB virus type C interactions with HIV: the role of envelope 
glycoproteins. J Viral Hepat. 2009;16:757-68.
 16. Reshetnyak VI, Karlovich TI, Ilchenko LU. Hepatitis G virus. World J Gastroenterol. 
2008;14:4725-34.
 17. Simmons JN, Leary TP, Dawson GJ, Pilot-Matias AS, Muerhoff AS, Schlauder GG, et 
al. Isolation of novel virus-like sequences associated with human hepatitis. Nat Med. 
1995;1:564-9.
 18. Souza IE, Allen JB, Xiang J, Klinzman D, Diaz R, Zhang S, et al. Effect of primer selection 
on estimates of GB virus C (GBV-C) prevalence and response to antiretroviral therapy 
for optimal testing for GBV-C viremia. J Clin Microbiol. 2006;44:3105-13. 
 19. Tacke M, Kiyosawa K, Stark K, Schlueter V, Ofenloch-Haehnle B, Hess G, et al. Detection 
of antibodies to a putative hepatitis G virus envelope protein. Lancet. 1997;349:318-
20. Erratum in: Lancet. 1997;349:736. 
 20. Tillmann HL, Heiken H, Knapik-Botor A, Heringlake S, Ockenga J, Wilber JC, et al. 
Infection with GB virus C and reduced mortality among HIV-infected patients. N 
Engl J Med. 2001;345:715-24. 
 21. Toyoda H, Fukuda Y, Hayakawa T, Takamatsu J, Saito, H. Effect of GB virus C/hepatitis 
G virus co-infection on the course of HIV infection in hemophilia patients in Japan. 
J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:209-13.
 22. Van der Bij AK, Kloosterboer N, Prins M, Boeser-Nunnink B, Geskus RB, Lange JM, et 
al. GB virus C coinfection and HIV-1 disease progression: The Amsterdam Cohort 
Study. J Infect Dis. 2005;191:678-85. 
 23. Williams CF, Klinzman D, Yamashita TE, Xiang J, Polgreen PM, Rinaldo C, et al. 
Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med. 
2004;350:981-90.
 24. Xiang J, George SL, Wünschmann S, Chang Q, Klinzman D, Stapleton JT. Inhibition of 
HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1α, 
MIP-1β, and SDF-1. Lancet. 2004;363:2040-6.
 25. Xiang J, Wünschmann S, Diekema DJ, Klinzman D, Patrick KD, George SL, et al. Effect 
of coinfection with GB virus C on survival among patients with HIV infection. N 
Engl J Med. 2001;345:707-14.
 26.  Zhang W, Chaloner K, Tillmann HL, Williams CF, Stapleton JT. Effect of early and late 
GB virus C viraemia on survival of HIV-infected individuals: a meta-analysis. HIV 
Medicine. 2006;7:173-80. 
 Received: 18 January 2011
 Accepted: 21 November 2011
